Gilead’s IDEAL PBC Trial Reaches Key Milestone, Setting Up a New Liver Disease Catalyst
Gilead Sciences (GILD) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The IDEAL Phase 3 study, officially titled “IDEAL: A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA),” aims to test whether seladelpar can help normalize key liver enzyme levels in people with PBC. This matters because many patients do not respond well to current therapy and still face long-term liver damage risks.
The study tests seladelpar 10 mg taken by mouth once daily against a matching placebo capsule over 52 weeks. The goal is to see if seladelpar can safely lower alkaline phosphatase and improve overall disease control in patients who cannot rely on UDCA alone.
This is an interventional Phase 3 trial where participants are randomly assigned to seladelpar or placebo in parallel groups. It is double-blind, meaning neither patients nor doctors know who receives seladelpar, and the main purpose is to assess how well the drug treats PBC compared with placebo.
The trial ran for 52 weeks of treatment, with the primary endpoint focused on alkaline phosphatase normalization at Week 52. The study is now listed as completed, and the record was last updated on June 2, 2026, signaling that key data have been collected even though results are not yet posted.
For investors, the completion and recent update of this pivotal PBC study are important catalysts for Gilead Sciences (GILD), as positive data could support a new liver disease franchise and diversify revenue beyond HIV and oncology. The outcome may also influence sentiment toward other cholestatic liver disease players and will be watched closely for any signal on future competition and pricing power.
The IDEAL study has completed treatment and the record has been recently updated, with further details available on the ClinicalTrials portal.
To learn more about GILD’s potential, visit the Gilead Sciences drug pipeline page.
